Medical devicemaker MicroTransponder wrapped up a $53 million Sequence E funding spherical led by US Enterprise Companions.
The elevate additionally included participation from GPG Ventures, Exceller Hunt Ventures, Osage College Companions, Motion Potential Enterprise Capital and the Vertical Group. The corporate mentioned it can use the capital to commercialize its Vivistim vagus nerve stimulation system, an implantable gadget that goals to enhance hand and arm mobility in stroke sufferers.
“Our buyers are energized by MicroTransponder’s imaginative and prescient to allow therapy for the hundreds of thousands of stroke survivors which have ongoing average to extreme higher limb impairment. Our purpose has all the time been to determine Vivistim Paired VNS because the gold-standard stroke rehabilitation intervention. At present is the day this remedy can assist extra stroke survivors get again to the day by day actions, hobbies and experiences they love,” CEO and director Richard Foust mentioned in an announcement.
Oma Fertility emerged from stealth final week with $37.5 million, together with $29 million in fairness and one other $8.5 million in debt financing.
The seed and Sequence A rounds had been led by JAZZ Enterprise Companions, Root Ventures, Mithril Capital, International Asset Capital and Free Solo Ventures. The debt facility got here from Silicon Valley Financial institution. The fertility startup’s first product is geared toward figuring out the healthiest sperm to enhance IVF outcomes.
“Oma Fertility is capitalizing on the chance to convey modern technological developments to the fertility area, assembly the calls for of rising infertility charges,” cofounder and CEO Gurjeet Singh mentioned in an announcement. “Our mission is to enhance outcomes for extra households dealing with fertility points and we try to create a spot the place everybody looking for to have a toddler has entry to essentially the most superior, profitable fertility remedies.”
Payer-focused healthcare knowledge startup Abacus Insights scooped up $28 million in Sequence C funding, bringing its complete elevate to $81 million.
The spherical was led by MultiPlan Company with participation from Blue Enterprise Fund, CRV, .406 Ventures, Horizon Healthcare Companies Inc. and Echo Well being Ventures. Abacus raised $35 million in Sequence B funding in 2020.
It plans to make use of the funding to develop its enterprise, enhance on its platform and rent extra staffers.
“This new funding validates our firm’s mission, which is to assist well being plans liberate well being knowledge,” CEO and founder Dr. Minal Patel mentioned in an announcement. “Doing so empowers shoppers to make higher well being decisions and physicians to make extra knowledgeable therapy selections. Payors additionally use the platform to drive effectivity of their enterprise which additional lowers prices for his or her members. We’re proud to companion with MultiPlan given their management place in knowledge and analytics serving almost each payor within the nation.”
Self-pay healthcare market Sesame raised $27 million in a Sequence B spherical led by GV.
Virgin Group, TeleSoft Companions, FMZ Ventures, Common Catalyst, Business Ventures, Coefficient Capital, Big Ventures and Alumni Ventures Group additionally participated within the elevate. Sesame plans to make use of the capital to develop the startup and launch its subscription program out of beta.
“Sesame gives better entry to healthcare for a significant proportion of the inhabitants, and we’re impressed by the corporate’s mission to drive higher affected person outcomes for underserved communities,” Cathy Friedman, govt enterprise companion at GV, mentioned in an announcement.
“Sesame presents a compelling alternative to develop a dynamic market at a scale not like any within the present U.S. healthcare ecosystem. We’re thrilled to companion with David Goldhill and the complete Sesame staff as they transfer into this subsequent part of progress.”